Lexiva for Laryngopharyngeal Reflux
(FLUTTER Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing Lexiva, an HIV drug, to help patients with moderate/severe LPR who haven't responded to other treatments. Lexiva works by blocking pepsin, which causes throat inflammation. The goal is to see if this drug can reduce LPR symptoms.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but if you are on five or more medications due to other health conditions, you may not be eligible to participate.
Are You a Good Fit for This Trial?
This trial is for adults over 18 with moderate to severe LPR, a throat condition causing cough and hoarseness. Participants must have tried acid-reducing meds without success and be confirmed to have LPR by specific tests. It's not for those over 65, pregnant or nursing women, or people with certain GI diseases, past stomach surgeries, suspected cancer in the throat area, or on many other medications.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Oral Fosamprenavir or placebo for 12 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Lexiva
Find a Clinic Near You
Who Is Running the Clinical Trial?
Medical College of Wisconsin
Lead Sponsor